MediWound (NASDAQ:MDWD) Stock Price Breaks Above 50-Day Moving Average – Time to Sell?

Shares of MediWound Ltd. (NASDAQ:MDWD) passed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $13.05 and traded as high as $13.67. MediWound shares last traded at $13.56, with a volume of 126,554 shares traded.

Analyst Ratings Changes

A number of equities research analysts recently commented on MDWD shares. Weiss Ratings lowered MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Oppenheimer reissued an “outperform” rating and set a $30.00 target price (down from $32.00) on shares of MediWound in a report on Friday, August 14th. TD Cowen restated a “buy” rating on shares of MediWound in a research report on Thursday, September 24th. Alliance Global Partners reaffirmed a “buy” rating on shares of MediWound in a report on Wednesday, September 16th. Finally, Wall Street Zen raised shares of MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, September 26th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, MediWound has a consensus rating of “Moderate Buy” and an average target price of $33.00.

MediWound Trading Down 4.0%

The firm has a 50-day moving average of $13.06 and a two-hundred day moving average of $15.23.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.01). MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The firm had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. As a group, equities analysts predict that MediWound Ltd. will post -2.37 EPS for the current year.

Insider Activity at MediWound

In related news, COO Shmuel Hess sold 3,958 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 9.20% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds.

MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.